News

Myeloproliferative neoplasms (or MPN) are disorders where parts of the bone marrow get overproduced, such as platelets (blood cells to stop bleeding), red blood cells (blood cells that carry oxygen in the body), or fibrous tissue in the bone marrow (like scar tissue.)  They can run in families but are usually sporadic, or isolated cases when they happen.  The Pediatric MPN Program is a joint program of the Division of Pediatric Hematology/Oncology at Weill Cornell Medicine and the NYP Komansky Children's Hospital, and the Richard T. Silver Myeloproliferative Neoplasm Center.    

Our team is also engaged in research, with the goal of bringing bench discoveries to the bedside, for better care and management of this rare disease.

Learn more

Find out more about MPN and keep up with program news at our website: 

Pediatric MPN Program at Weill Cornell Medicine

Bullying is one of the most common traumatic challenges faced by children today. In fact, New York state has the second highest rate of reported bullying for children in grades K through 12. 

The majority of bullying takes place at school. Here, the Weill Cornell Medicine Department of Pediatrics provides simple strategies for parents and children to deal with bullying issues, in preparation for the start of the new school year. 

Read more / go to full article

Two thirds of children in the pediatric intensive care unit (PICU) who receive transfusions of platelets—a component of the blood that helps it to clot—do so to prevent bleeding, according to a new study from Weill Cornell Medicine and NewYork-Presbyterian investigators. The other third of patients receive the transfusions to stop active bleeding. 

Some children who receive platelet transfusions for preventive, or prophylactic, purposes may not need them, said the study’s lead author Dr. Marianne Nellis, an assistant professor of pediatrics at Weill Cornell Medicine and a pediatric intensivist at NewYork-Presbyterian/Weill Cornell Medical Center.

Full Story 

Peanut allergy is becoming increasingly common in the United States, with a tripling in reported peanut allergy prevalence over 11 years.  In 2015, for the first time, a landmark study provided evidence of an intervention that significantly reduces the risk of developing peanut allergy.  What is this miracle treatment?  As it turns out, it is peanut, early and often!  Read on to learn whether your child might benefit from early introduction of peanut, and what role the allergist plays in facilitating introduction of peanut and other allergenic foods.

When should I introduce peanut to my infant?

Based on convincing evidence (detailed at the end of this document) that early introduction of peanut reduces risk of developing peanut allergy in at-risk infants, the National Institute of Allergy and Infectious Diseases (NIAID) has created guidelines for introduction of peanut as follows:

We are pleased to announce the appointment of Snezana Nena Osorio, M.D., M.S. as Vice Chair for Quality and Patient Safety in the Department of Pediatrics. In this new position, Dr. Osorio will lead and expand the Department’s Quality and Patient Safety initiatives. She will continue to provide clinical care in the Division of General Academic Pediatrics and serve as an educator in the Department of Pediatrics.

Dr. Osorio brings demonstrated experience, innovation, and leadership in quality and safety. Since joining the Department of Pediatrics at Weill Cornell Medicine, Dr. Osorio has helped to develop the Patient and Family-Centered care (PFCC) Program, including the formation of the Komansky Children’s Hospital Family Advisory Council (KCH FAC) and introducing Family Centered Rounds. KCH FAC is a group of dedicated parents whose children have been hospitalized at NewYork-Presbyterian. The FAC has become a vital part of family-centered care, working with hospital staff to improve safety measures and the patient experience with initiatives such as the Family Faculty and Family Centered Rounds. This work was supported by a Clinical Scholar Award for Patient Safety and Quality from the Department of Pediatrics.

Before Dashiel was born, Alissa had expected her son to be hospitalized for two weeks. Because “Dash” had congenital heart defects along with Down syndrome, she wanted him to have the best care — even if it meant driving two hours from her home in the Hudson Valley to NewYork-Presbyterian’s Upper East Side Manhattan campus and the NYP Komansky Children's Hospital.  But after Dash underwent surgery to place a shunt into his pulmonary artery, leading to his aorta, to make sure he had enough oxygenated blood going into his lungs, he suffered troubled breathing and dangerously high fevers. Two weeks turned into six months, making the hospital the only home he’d ever known. 

The family endured their greatest challenges with help from a broad community of caregivers, from the friends and family who watched the kids to the nurses who loved and cared for Dash like Alissa did.

Learn more about Dashiel's Story

Delirium is a frequent occurrence among children hospitalized with cancer, affecting nearly one in five patients, according to new research from Weill Cornell Medicine and NewYork-Presbyterian.

The study, published Nov. 21 in the Journal of Pediatrics, revealed that children who were either younger than 5 years old, had an underlying brain tumor, were recovering from surgery or receiving benzodiazepines — a class of drugs that treat anxiety, nervousness, seizures and other conditions by altering chemical signals in the brain — were at greatest risk for delirium, a mental state characterized by changes in alertness, cognition or awareness. The investigators say their findings demonstrate that children with cancer are at risk for developing delirium, and underscore the importance of routine screenings for the condition, which is associated with poor health outcomes, prolonged hospital stays and increased distress for patients and their families.

Analise Scarpaci's career debut also changed her long-term health.

Rett Syndrome: From the Clinic to Genomes, Epigenomes, and Neural Circuits featuring Huda Y. Zoghbi, MD Ralph D. Feigin Professor of Pediatrics, Neuroscience, and Molecular and Human Genetics at Baylor College of Medicine Investigator, Howard Hughes Medical Institute Director, Jan and Dan Duncan Neurological Research Institute at Texas Children’s Hospital Reception to follow at 5:00 PM. Rett syndrome is a delayed-onset childhood disorder, typically found in girls, that causes a broad range of severe neuropsychiatric disabilities, including loss of the ability to speak and socialize, and the development of tremors, ataxia, seizures, and stereotypic hand-wringing movements. The Zoghbi lab discovered that mutations in the gene MECP2 cause Rett syndrome, and before long it became clear that mutations in MECP2 can also cause autism and other neuropsychiatric phenotypes. Using genetically-engineered mice, the Zoghbi lab learned that the brain is acutely sensitive to MeCP2 levels; both decreases and increases in the amount of MeCP2 protein can lead to neurological problems that are also observed in humans. The research team showed that normalizing MeCP2 levels can reverse disease-like features in a mouse model of the human MECP2 duplication syndrome, a disorder that is usually found in boys and results from excess MeCP2. Zoghbi and collaborators have been gradually pinpointing the neurons and circuit abnormalities that mediate various symptoms.

Pediatrics Weill Cornell Medicine Appointments & Referrals: (646) 962-KIDS (646) 962-5437 Chair's Office: Weill Cornell Medicine 525 E 68th St.
Box 225
New York, NY 10065 (646) 962-5437